SomaLogic

SomaLogic, Inc. is a commercial-stage proteomics company, which built an integrated proteomics platform for robust, high throughput proteomics analysis, research and clinical applications. The company was founded by Larry Gold in 2000 and is headquartered in Boulder, CO.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

SomaLogic reports mixed Q4 results, eyes growth through innovation

SomaLogic navigated a mixed financial performance in Q4 2022, focusing on cost management.
The company is strengthening its position in the life sciences sector with innovative products.
Challenges lie in leadership transitions and balancing expenses with growth investments.
Opportunities abound in strategic collaborations, product launches, and market expansion.

SomaLogic reports Q1 revenue growth amid margin challenges

SomaLogic's Q1 performance reflects revenue growth initiatives amidst financial challenges.
Strategic partnerships, expansion plans, and product launches position the company for future growth.
Addressing margin issues and optimizing expenses are critical for achieving profitability and meeting revenue targets.

SomaLogic reports robust Q2 revenue growth, eyes international partnerships

SomaLogic's Q2 2023 performance reflects strong revenue growth and improved cost management, yet challenges persist in achieving profitability.
Strategic strengths include experienced leadership, international expansion, and partnerships driving growth opportunities in the life sciences sector.
Maintaining operational rigor, enhancing margins, and leveraging cash reserves position SomaLogic for sustainable growth and market leadership.

SomaLogic reports revenue growth and strategic merger for future growth

SomaLogic's Q3 2023 performance showed revenue growth and cost management improvements, with a strong cash position. Strategic partnerships and merger offer growth opportunities.
Challenges include revenue decline on a GAAP basis and ongoing EBITDA losses. Opportunities lie in new indications, geographic expansion, and biopharma performance drivers.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK and BOULDER, Colo., Nov. 03, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the upcoming Stifel 2021 Virtual Healthcare Conference.

SomaLogic to Present at the Stifel 2021 Virtual Healthcare Conference

BOULDER, Colo., Nov. 01, 2021 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a strategic collaboration with one of the nation's leading academic medical centers, University Hospitals Cleveland Medical Center, where they will evaluate the impact of the company's SomaSignal™ tests on the medical management of diabetic patients who are at a higher risk of cardiovascular disease.

SomaLogic announces strategic collaboration with University Hospitals Cleveland Medical Center to treat diabetic patients at high risk of cardiovascular disease

BOULDER, Colo., Oct. 28, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the third quarter 2021 before the market opens on Monday, November 15, 2021. Company management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.

SomaLogic to Announce Third Quarter 2021 Financial Results

BOULDER, Colo., Oct. 20, 2021 (GLOBE NEWSWIRE) -- In the largest proteogenomic study of its kind to date, an international research team led by scientists at the Berlin Institute of Health at Charité and the University of Cambridge used SomaLogic's (NASDAQ: SLGC) SomaScan® Platform to generate data on thousands of proteins in human blood. They then combined this information with genetic data to reveal a network of gene-protein connections that drive human diseases that span a variety of medical specialties and organ systems. This study was recently published in Science.

A new study using the SomaScan® Platform makes the connection between genes and proteins and their impact on human disease

SomaLogic was founded in 2000 by Larry Gold, who earlier founded NeXstar Pharmaceuticals, which was acquired by Gilead (GILD) for $550M. Institutional holders in the company include Ark Investment Management, Perceptive Advisors, Illumina, Softbank, Redmile Group, etc.

SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics

NEW YORK and BOULDER, Colo., Sept. 22, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today is announcing upcoming conference participation in addition to its analyst meeting.

SomaLogic Announces Upcoming Conference Participation and Analyst Meeting

The stock price of SomaLogic (Nasdaq: SLGC) increased pre-market today. This is why it happened.

SLGC Stock: Why It Increased Today

NEW YORK and BOULDER, Colo., Sept. 13, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, will host a virtual Analyst and Investor Meeting on Tuesday, September 28, 2021 from 11:00 a.m. to approximately 1:00 p.m. Eastern Time. The event will feature presentations from company leaders outlining SomaLogic's technology, addressable market opportunity, financial outlook, and key metrics for success as it continues its scientific and commercial progress. Speaker remarks will be followed by a live Q&A session.

SomaLogic Announces Analyst and Investor Meeting on September 28

BOULDER, Colo., Sept. 13, 2021 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a strategic collaboration with leading health system UPMC to explore how the large-scale study of proteins and their functions in the body can effectively be used in clinical care.

SomaLogic announces strategic collaboration with UPMC to tailor clinical care through proteomics technology

NEW YORK and BOULDER, Colo., Sept. 08, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the six months ended June 30, 2021.

SomaLogic Reports First Half of 2021 Financial Results

NEW YORK and BOULDER, Colo., Sept. 07, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the upcoming Morgan Stanley 19th Annual Global Healthcare Conference.

SomaLogic to Present at Morgan Stanley 19th Annual Global Healthcare Conference

CM Life Sciences II Inc - Unit

NEW YORK and BOULDER, Colo., Sept. 01, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it has completed its business combination with CM Life Sciences II, Inc. (Nasdaq: CMIIU), a special purpose acquisition company sponsored by affiliates of leading healthcare and life sciences fund advisors Casdin Capital and Corvex Management. Following the transaction, the combined company was renamed SomaLogic, Inc., and its Class A common stock and warrants will begin trading on the Nasdaq Global Market (“Nasdaq”) on September 2, 2021 under the symbols “SLGC” and “SLGCW,” respectively. The business combination and concurrent private placement were approved by CM Life Sciences II shareholders at its special meeting held on August 31st, 2021.

SomaLogic Closes Business Combination and Will Begin Trading Under the Ticker “SLGC” on the Nasdaq Stock Exchange

News for SomaLogic Stock (SLGC)